Targeting Macrophage Epsins to Reverse Atherosclerosis

HomeCirculation ResearchVol. 132, No. 1Targeting Macrophage Epsins to Reverse Atherosclerosis No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextTargeting Macrophage Epsins to Reverse Atherosclerosis Fang Li and Hanrui Zhang Fang LiFang Li https://orcid.org/0000-0002-1383-9724 Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. Search for more papers by this author and Hanrui ZhangHanrui Zhang Correspondence to: Hanrui Zhang, MB, PhD, Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 W 168th St, P&S10-401 New York, NY 10032. Email E-mail Address: [email protected] Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. Search for more papers by this author Originally published5 Jan 2023https://doi.org/10.1161/CIRCRESAHA.122.322273Circulation Research. 2023;132:7–9This article is a commentary on the followingEpsin Nanotherapy Regulates Cholesterol Transport to Fortify Atheroma RegressionFootnotesFor Sources of Funding and Disclosures, see page 9.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Hanrui Zhang, MB, PhD, Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 W 168th St, P&S10-401 New York, NY 10032. Email [email protected]columbia.eduReferences1. Björkegren JLM, Lusis AJ. Atherosclerosis: recent developments.Cell. 2022; 185:1630–1645. doi: 10.1016/j.cell.2022.04.004CrossrefMedlineGoogle Scholar2. Susser LI, Rayner KJ. Through the layers: how macrophages drive atherosclerosis across the vessel wall.J Clin Invest. 2022; 132:e157071. doi: 10.1172/JCI157011CrossrefMedlineGoogle Scholar3. Doran AC. Inflammation resolution: implications for atherosclerosis.Circ Res. 2022; 130:130–148. doi: 10.1161/CIRCRESAHA.121.319822LinkGoogle Scholar4. Chen W, Schilperoort M, Cao Y, Shi J, Tabas I, Tao W. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.Nat Rev Cardiol. 2022; 19:228–249. doi: 10.1038/s41569-021-00629-xCrossrefMedlineGoogle Scholar5. Cui K, Gao X, Wang B, Wu H, Arulsamy K, Dong Y, Xiao Y, Jiang X, Malovichko MV, Li K, et al. Epsin nanotherapy regulates cholesterol transport to fortify atheroma regression.Circ Res. 2022 132:e22–e42.doi: 10.1161/CIRCRESAHA.122.321723LinkGoogle Scholar6. Bhattacharjee S, Lee Y, Zhu B, Wu H, Chen Y, Chen H. Epsins in vascular development, function and disease.Cell Mol Life Sci. 2021; 78:833–842. doi: 10.1007/s00018-020-03642-4CrossrefMedlineGoogle Scholar7. Chen H, Fre S, Slepnev VI, Capua MR, Takei K, Butler MH, Di Fiore PP, De Camilli P. Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis.Nature. 1998; 394:793–797. doi: 10.1038/29555CrossrefMedlineGoogle Scholar8. Rosenthal JA, Chen H, Slepnev VI, Pellegrini L, Salcini AE, Di Fiore PP, De Camilli P. The epsins define a family of proteins that interact with components of the clathrin coat and contain a new protein module.J Biol Chem. 1999; 274:33959–33965. doi: 10.1074/jbc.274.48.33959CrossrefMedlineGoogle Scholar9. Brophy ML, Dong Y, Tao H, Yancey PG, Song K, Zhang K, Wen A, Wu H, Lee Y, Malovichko MV, et al. Myeloid-specific deletion of Epsins 1 and 2 reduces atherosclerosis by preventing LRP-1 downregulation.Circ Res. 2019; 124:e6–e19. doi: 10.1161/CIRCRESAHA.118.313028LinkGoogle Scholar10. Tao W, Yurdagul A, Kong N, Li W, Wang X, Doran AC, Feng C, Wang J, Islam MA, Farokhzad OC, et al. siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice.Sci Transl Med. 2020; 12: eaay1063. doi: 10.1126/scitranslmed.aay1063CrossrefGoogle Scholar11. Dong Y, Lee Y, Cui K, He M, Wang B, Bhattacharjee S, Zhu B, Yago T, Zhang K, Deng L, et al. Epsin-mediated degradation of IP3R1 fuels atherosclerosis.Nat Commun. 2020; 11:3984. doi: 10.1038/s41467-020-17848-4CrossrefMedlineGoogle Scholar12. Zheng R, Zhang Y, Tsuji T, Gao X, Wagner A, Yosef N, Chen H, Zhang L, Tseng Y-H, Chen K. MEBOCOST: Metabolite-mediated cell communication modeling by single cell transcriptome.bioRxiv. Preprint posted online September 11, 2022. doi: 10.1101/2022.05.30.494067CrossrefGoogle Scholar13. Wang Y, Dubland JA, Allahverdian S, Asonye E, Sahin B, Jaw JE, Sin DD, Seidman MA, Leeper NJ, Francis GA. Smooth muscle cells contribute the majority of foam cells in ApoE (Apolipoprotein E)-deficient mouse atherosclerosis.Arterioscler Thromb Vasc Biol. 2019; 39:876–887. doi: 10.1161/ATVBAHA.119.312434LinkGoogle Scholar14. Pan H, Xue C, Auerbach BJ, Fan J, Bashore AC, Cui J, Yang DY, Trignano SB, Liu W, Shi J, et al. Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human.Circulation. 2020; 142:2060–2075. doi: 10.1161/CIRCULATIONAHA.120.048378LinkGoogle Scholar15. Donadon M, Torzilli G, Cortese N, Soldani C, Di Tommaso L, Franceschini B, Carriero R, Barbagallo M, Rigamonti A, Anselmo A, et al. Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis.J Exp Med. 2020; 217:e20191847. doi: 10.1084/jem.20191847CrossrefMedlineGoogle Scholar16. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma.Nat Immunol. 2009; 10:943–948. doi: 10.1038/ni.1781CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesEpsin Nanotherapy Regulates Cholesterol Transport to Fortify Atheroma RegressionKui Cui, et al. Circulation Research. 2023;132:e22-e42 January 6, 2023Vol 132, Issue 1 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.122.322273PMID: 36603063 Originally publishedJanuary 5, 2023 KeywordslipidsEditorialsmacrophagesnanoparticleatherosclerosisPDF download Advertisement